TY - JOUR
T1 - Blood component use and associated costs after standard dose chemotherapy-a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany
AU - Paessens, Bernadette
AU - Ihbe-Heffinger, Angela
AU - Von Schilling, Christoph
AU - Shlaen, Rita
AU - Bernard, Rudolf
AU - Peschel, Christian
AU - Schramm, Wolfgang
AU - Berger, Karin
N1 - Funding Information:
Acknowledgement This investigator-initiated study was supported by the Lilly Deutschland GmbH, Bad Homburg, Germany, and the Amgen GmbH, Munich, Germany. The study sponsors were not involved in the study design, data collection, in the analysis and interpretation of data, in the writing of the manuscript and in the decision to submit the manuscript for publication.
PY - 2012/5
Y1 - 2012/5
N2 - Purpose The purpose of this study was to describe blood component (BC) use and respective cost after standard dose chemotherapy (CT) in routine hospital care. Methods Analysis of data from a prospective, multicenter, longitudinal, observational study on lymphoproliferative disorder (LPD) and non-small cell lung cancer (NSCLC) patients undergoing first or second line standard dose (immuno-)CT. Data were collected from patient interviews and pre-planned chart reviews. Costs of BC are presented from provider perspective. Results One hundred eighty patients (n=85 NSCLC, n=95 LPD) receiving 189 CT lines/633 CT cycles) were evaluable (mean±SD age, 59±13.2 years, 68% stage III/IV, 14% Eastern Cooperative Oncology Group≥2). During 11% of cycles, BC were transfused to 27% of patients (n=49; n=22 NSCLC, n=27 LPD). Of 310 transfused units (TU), 68% were red blood cells (RBC). Mean number of TU per cycle with transfusion was 3.3±2.9 (median=2, range=2.17) for RBC, 4.8±6.8 (median=2, range=1.23) for platelets (PLT) and 12.8±14.6 (median=8, range=2.33) for fresh frozen plasma (FFP). Fifteen per cent of RBC units, 60% of PLT units and 92% of FFP in this study were transfused in cycles with sepsis. Mean BC cost per CT line were €602±1,458 (median=135, range=135-9,385; NSCLC: €292±376, median=135, range=135-2,124; LPD: €1,010±2,137, median=212, range=135-9,385, p=0.2137). For 55% of transfused RBC units, haemoglobin levels on the day of transfusion were 8.0.8.9 g/dl, for 38% <8 g/dl and for 7%≥9 g/dl. Seventy-five per cent of PLT units were transfused at a PLT count <11,000/μl and 21% at 20,000-11,000/μl. Conclusions The results reflect the diversity of BC use after standard dose CT. High transfusion need is associated with infectious complications, i.e. sepsis emphasising the need for adequate prophylaxis and further knowledge of baseline risk factors.
AB - Purpose The purpose of this study was to describe blood component (BC) use and respective cost after standard dose chemotherapy (CT) in routine hospital care. Methods Analysis of data from a prospective, multicenter, longitudinal, observational study on lymphoproliferative disorder (LPD) and non-small cell lung cancer (NSCLC) patients undergoing first or second line standard dose (immuno-)CT. Data were collected from patient interviews and pre-planned chart reviews. Costs of BC are presented from provider perspective. Results One hundred eighty patients (n=85 NSCLC, n=95 LPD) receiving 189 CT lines/633 CT cycles) were evaluable (mean±SD age, 59±13.2 years, 68% stage III/IV, 14% Eastern Cooperative Oncology Group≥2). During 11% of cycles, BC were transfused to 27% of patients (n=49; n=22 NSCLC, n=27 LPD). Of 310 transfused units (TU), 68% were red blood cells (RBC). Mean number of TU per cycle with transfusion was 3.3±2.9 (median=2, range=2.17) for RBC, 4.8±6.8 (median=2, range=1.23) for platelets (PLT) and 12.8±14.6 (median=8, range=2.33) for fresh frozen plasma (FFP). Fifteen per cent of RBC units, 60% of PLT units and 92% of FFP in this study were transfused in cycles with sepsis. Mean BC cost per CT line were €602±1,458 (median=135, range=135-9,385; NSCLC: €292±376, median=135, range=135-2,124; LPD: €1,010±2,137, median=212, range=135-9,385, p=0.2137). For 55% of transfused RBC units, haemoglobin levels on the day of transfusion were 8.0.8.9 g/dl, for 38% <8 g/dl and for 7%≥9 g/dl. Seventy-five per cent of PLT units were transfused at a PLT count <11,000/μl and 21% at 20,000-11,000/μl. Conclusions The results reflect the diversity of BC use after standard dose CT. High transfusion need is associated with infectious complications, i.e. sepsis emphasising the need for adequate prophylaxis and further knowledge of baseline risk factors.
KW - Anaemia/chemically induced/economics
KW - Blood component transfusion
KW - Combined antineoplastic treatment protocols/adverse effects
KW - Drug toxicity/ prevention and control
KW - Erythrocyte transfusion
KW - Plasma/therapeutic use
KW - Platelet transfusion
KW - Thrombocytopenia/chemically induced/economics
UR - http://www.scopus.com/inward/record.url?scp=84863443623&partnerID=8YFLogxK
U2 - 10.1007/s00520-011-1173-1
DO - 10.1007/s00520-011-1173-1
M3 - Article
C2 - 21562801
AN - SCOPUS:84863443623
SN - 0941-4355
VL - 20
SP - 1011
EP - 1021
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 5
ER -
